title: Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
abstract: In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life.
authors.affiliation: Wake Forest University School of Medicine, Winston Salem, North Carolina 27157-1071, USA. sfeldman@wfubmc.edu
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
authors.forename: Alexa Boer
authors.initials: AB
authors.lastname: Kimball
authors.forename: Gerald G
authors.initials: GG
authors.lastname: Krueger
authors.forename: J Michael
authors.initials: JM
authors.lastname: Woolley
authors.forename: Deepa
authors.initials: D
authors.lastname: Lalla
authors.forename: Angelika
authors.initials: A
authors.lastname: Jahreis
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept